JP2021505578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505578A5 JP2021505578A5 JP2020530585A JP2020530585A JP2021505578A5 JP 2021505578 A5 JP2021505578 A5 JP 2021505578A5 JP 2020530585 A JP2020530585 A JP 2020530585A JP 2020530585 A JP2020530585 A JP 2020530585A JP 2021505578 A5 JP2021505578 A5 JP 2021505578A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- independently
- compound
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 *COP([*+])(OP(*)(N(*)C(*)(*)C(O*)=O)=*)=O Chemical compound *COP([*+])(OP(*)(N(*)C(*)(*)C(O*)=O)=*)=O 0.000 description 27
- JTGPFMFVEHGDKC-RVEOCHJUSA-N CC(OC([C@H]1[n]2c(nc(nc3N)F)c3nc2)C11O)=C1O Chemical compound CC(OC([C@H]1[n]2c(nc(nc3N)F)c3nc2)C11O)=C1O JTGPFMFVEHGDKC-RVEOCHJUSA-N 0.000 description 1
- ISRGMGHEBIGSQG-ZCFIWIBFSA-N CC(O[C@H](C1)[n]2c(nc(nc3N)Cl)c3nc2)=C1O Chemical compound CC(O[C@H](C1)[n]2c(nc(nc3N)Cl)c3nc2)=C1O ISRGMGHEBIGSQG-ZCFIWIBFSA-N 0.000 description 1
- PFADMNKPUSCMNL-SPDVFEMOSA-N CC[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O Chemical compound CC[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O PFADMNKPUSCMNL-SPDVFEMOSA-N 0.000 description 1
- LMMOTBVCCYRRBE-JXBXZBNISA-N CC[C@H](C(C1)O)O[C@H]1[n]1c(nc(nc2N)Cl)c2nc1 Chemical compound CC[C@H](C(C1)O)O[C@H]1[n]1c(nc(nc2N)Cl)c2nc1 LMMOTBVCCYRRBE-JXBXZBNISA-N 0.000 description 1
- SJXVLXDULLOMPB-FYXMTTTISA-N CC[C@H](C(C12)O)O[F]1[C@H]2[n]1c2nc(Cl)nc(N)c2nc1 Chemical compound CC[C@H](C(C12)O)O[F]1[C@H]2[n]1c2nc(Cl)nc(N)c2nc1 SJXVLXDULLOMPB-FYXMTTTISA-N 0.000 description 1
- GJPQKIQISJHKEA-ZJXFTUPMSA-N C[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O Chemical compound C[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O GJPQKIQISJHKEA-ZJXFTUPMSA-N 0.000 description 1
- LOQMDCLQQLZUPM-QDCZBHAESA-N C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)Cl)c4nc3)O)OC12F Chemical compound C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)Cl)c4nc3)O)OC12F LOQMDCLQQLZUPM-QDCZBHAESA-N 0.000 description 1
- ODUODVIWIGWIBR-QDCZBHAESA-N C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)F)c4nc3)O)OC12O Chemical compound C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)F)c4nc3)O)OC12O ODUODVIWIGWIBR-QDCZBHAESA-N 0.000 description 1
- WGYIFCKYIGZKEV-QCZWIRADSA-N C[C@H](C1O)OC([C@H]2N(C=CC(N)=N3)C3=O)C12F Chemical compound C[C@H](C1O)OC([C@H]2N(C=CC(N)=N3)C3=O)C12F WGYIFCKYIGZKEV-QCZWIRADSA-N 0.000 description 1
- ZGHWAIXFECZGJH-RRVQCMCFSA-N Nc1nc(Cl)nc2c1nc[n]2[C@@H](C12)C1O[C@H](COP(O)(OP(N(CCC1)[C@@H]1C(OCc1ccccc1)=O)(Oc1ccccc1)=O)=O)C2O Chemical compound Nc1nc(Cl)nc2c1nc[n]2[C@@H](C12)C1O[C@H](COP(O)(OP(N(CCC1)[C@@H]1C(OCc1ccccc1)=O)(Oc1ccccc1)=O)=O)C2O ZGHWAIXFECZGJH-RRVQCMCFSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1720279.7 | 2017-12-05 | ||
| GBGB1720279.7A GB201720279D0 (en) | 2017-12-05 | 2017-12-05 | Anticancer compounds |
| PCT/GB2018/053525 WO2019110991A1 (en) | 2017-12-05 | 2018-12-05 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505578A JP2021505578A (ja) | 2021-02-18 |
| JP2021505578A5 true JP2021505578A5 (https=) | 2021-12-23 |
| JP7268819B2 JP7268819B2 (ja) | 2023-05-08 |
Family
ID=60950385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530585A Active JP7268819B2 (ja) | 2017-12-05 | 2018-12-05 | 抗癌剤化合物としてのヌクレオシドのジホスフェートホスホルアミデートの塩 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11560400B2 (https=) |
| EP (2) | EP4043471A1 (https=) |
| JP (1) | JP7268819B2 (https=) |
| KR (1) | KR20200092980A (https=) |
| CN (1) | CN111527098A (https=) |
| AU (1) | AU2018379713A1 (https=) |
| BR (1) | BR112020011221A2 (https=) |
| CA (1) | CA3082269A1 (https=) |
| CL (1) | CL2020001479A1 (https=) |
| DK (1) | DK3720864T3 (https=) |
| EA (1) | EA202091218A1 (https=) |
| ES (1) | ES2910165T3 (https=) |
| GB (1) | GB201720279D0 (https=) |
| HR (1) | HRP20220451T1 (https=) |
| IL (1) | IL274808B2 (https=) |
| MA (2) | MA51006A (https=) |
| MX (1) | MX2020005850A (https=) |
| PH (1) | PH12020550728A1 (https=) |
| PL (1) | PL3720864T3 (https=) |
| PT (1) | PT3720864T (https=) |
| SG (1) | SG11202004342TA (https=) |
| WO (1) | WO2019110991A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3224268T (lt) | 2014-11-28 | 2019-09-25 | NuCana plc | Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| CN116768949B (zh) * | 2022-07-12 | 2026-03-03 | 南京工业大学 | 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| US20100297079A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| DK3031812T3 (en) | 2011-03-01 | 2018-09-17 | NuCana plc | CHEMICAL COMPOUNDS |
| WO2014124430A1 (en) * | 2013-02-11 | 2014-08-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| LT3043803T (lt) | 2013-09-11 | 2022-08-10 | Emory University | Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas |
| CN105646629A (zh) | 2014-11-25 | 2016-06-08 | 广州市恒诺康医药科技有限公司 | L-核苷类化合物及其应用 |
| LT3224268T (lt) | 2014-11-28 | 2019-09-25 | NuCana plc | Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai |
| CN107428792B (zh) * | 2014-12-15 | 2023-01-24 | 埃默里大学 | 用于治疗乙型肝炎病毒的磷酰胺 |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| WO2017106710A1 (en) | 2015-12-17 | 2017-06-22 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US20190085013A1 (en) | 2016-03-07 | 2019-03-21 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
-
2017
- 2017-12-05 GB GBGB1720279.7A patent/GB201720279D0/en not_active Ceased
-
2018
- 2018-12-05 KR KR1020207016514A patent/KR20200092980A/ko not_active Withdrawn
- 2018-12-05 ES ES18819340T patent/ES2910165T3/es active Active
- 2018-12-05 EA EA202091218A patent/EA202091218A1/ru unknown
- 2018-12-05 JP JP2020530585A patent/JP7268819B2/ja active Active
- 2018-12-05 WO PCT/GB2018/053525 patent/WO2019110991A1/en not_active Ceased
- 2018-12-05 MX MX2020005850A patent/MX2020005850A/es unknown
- 2018-12-05 BR BR112020011221-6A patent/BR112020011221A2/pt not_active IP Right Cessation
- 2018-12-05 EP EP21218125.9A patent/EP4043471A1/en not_active Withdrawn
- 2018-12-05 PT PT188193403T patent/PT3720864T/pt unknown
- 2018-12-05 EP EP18819340.3A patent/EP3720864B1/en active Active
- 2018-12-05 PL PL18819340T patent/PL3720864T3/pl unknown
- 2018-12-05 AU AU2018379713A patent/AU2018379713A1/en not_active Abandoned
- 2018-12-05 SG SG11202004342TA patent/SG11202004342TA/en unknown
- 2018-12-05 DK DK18819340.3T patent/DK3720864T3/da active
- 2018-12-05 US US16/769,635 patent/US11560400B2/en active Active
- 2018-12-05 CN CN201880078576.6A patent/CN111527098A/zh active Pending
- 2018-12-05 HR HRP20220451TT patent/HRP20220451T1/hr unknown
- 2018-12-05 MA MA051006A patent/MA51006A/fr unknown
- 2018-12-05 CA CA3082269A patent/CA3082269A1/en active Pending
- 2018-12-05 MA MA051007A patent/MA51007A/fr unknown
-
2020
- 2020-05-20 IL IL274808A patent/IL274808B2/en unknown
- 2020-05-28 PH PH12020550728A patent/PH12020550728A1/en unknown
- 2020-06-03 CL CL2020001479A patent/CL2020001479A1/es unknown
-
2022
- 2022-12-16 US US18/083,089 patent/US20230192750A1/en not_active Abandoned